CD274 and non-small cell lung carcinoma: The level of this expression is measured by the immunohistochemical analysis, whereby patients with advanced stage NSCLC and PD-L1 expression of at least 50% of tumor cells (tumor proportion score or TPS 50%) have benefited from the therapy with anti-PD-1 and anti-PD-L1 immunotherapeutics in terms of survival and reduction of adverse events compared to standard chemotherapy.